We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    LVGN7409
Previous Study | Return to List | Next Study

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04635995
Recruitment Status : Recruiting
First Posted : November 19, 2020
Last Update Posted : March 8, 2023
Information provided by (Responsible Party):
Lyvgen Biopharma Holdings Limited

Brief Summary:

LVGN7409 is a humanized monoclonal antibody that specifically binds to CD40, and acts as an agonist against CD40.

This first in human study of LVGN7409 is designed to establish the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) as well as the recommended Phase 2 dose(s) (RP2D) of LVGN7409, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody and/or CD137 agonist in the treatment of advanced or metastatic malignancy.

Condition or disease Intervention/treatment Phase
Cancer Biological: LVGN7409 Phase 1

Detailed Description:
This is an open-label, non-randomized, two-stage, FIH Phase 1 study, utilizing an accelerated dose escalation followed by a traditional 3 + 3 dose escalation algorithm to identify the MTD and/or RDE and RP2D of LVGN7409 as a single agent (monotherapy) and in combination with anti-PD-1 antibody and/or CD137 agonist. The first stage of the study is the dose escalation phase (i.e., Phase 1a). The second stage of the study is the dose expansion phase (i.e., Phase 1b). During the study, dose interruption(s) and/or delay(s) may be implemented based on toxicity. Dose modifications are not permitted. Intra-patient dose escalations will be allowed for the early dose cohorts (single-patient dose groups) in Phase 1a Part 1. Patients will be considered evaluable for safety and tolerability if they receive at least one dose of LVGN7409 or anti-PD-1 antibody and/or CD137 agonist at the specified cohort dose. Patients in all parts of the trial will remain on therapy until confirmed disease progression or for 2 years, whichever occurs first. However, patients who are clinically unstable will discontinue following the initial assessment of disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 Agonist Antibody) as a Single Agent, in Combination With LVGN3616 (Anti-PD-1 Antibody), and in Combination With LVGN3616 and LVGN6051 (CD137 Agonist Antibody) in Patients With Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy
Actual Study Start Date : December 11, 2020
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Experimental: Monotherapy dose escalation
The monotherapy dose escalation phase includes 8 dose levels of LVGN7409. Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Biological: LVGN7409
IV infusion once every 3 weeks (Q3W).

Primary Outcome Measures :
  1. Treatment-emergent adverse events (TEAEs) [ Time Frame: up to 24 months ]
    determination of DLTs and serious AEs (SAEs) of LVGN7409 as monotherapy. Adverse events will be assessed, and severity will be assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

  2. RP2D of LVGN7409 as monotherapy [ Time Frame: up to 24 months ]
    determination of MTD, RDE and/or RP2D of LVGN7409 as monotherapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females aged ≥ 18 years.
  • Ability to understand and willingness to sign a written informed consent document.
  • Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.
  • Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.
  • Adequate bone marrow, liver, and renal functions
  • Men and women of childbearing potential must agree to take highly effective contraceptive methods.
  • Patients should recover from all reversible AEs of previous anticancer therapies to baseline.
  • Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy.

Exclusion Criteria:

  • Prior therapy with anti-CD40 therapy.
  • Receipt of systemic anticancer therapy or radiotherapy within certain period of time.
  • Prior exposure to immune-therapeutics experienced Grade ≥ 3 drug-related toxicity, or a toxicity requiring discontinuation.
  • Received a live-virus vaccine within 30 days of the first dose of study drug.
  • Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.
  • History of Grade ≥ 3 immune-related AEs (irAEs).
  • Prolonged QT syndrome, or clinically significant cardiac condition.
  • Receiving an immunologically based treatment for any reason.
  • History or current active or chronic autoimmune disease.
  • Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage.
  • Female patients who are pregnant or breastfeeding.
  • History of hemorrhagic or ischemic stroke within the last 6 months.
  • Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04635995

Layout table for location contacts
Contact: Lynn Jiang, PhD 1-484-686-9652 lynn.jiang@lyvgen.com

Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030-3722
Contact: Yi-Hsin Hsu, PhD    713-794-3601    YHsu1@mdanderson.org   
Sponsors and Collaborators
Lyvgen Biopharma Holdings Limited
Layout table for additonal information
Responsible Party: Lyvgen Biopharma Holdings Limited
ClinicalTrials.gov Identifier: NCT04635995    
Other Study ID Numbers: LVGN7409-101
First Posted: November 19, 2020    Key Record Dates
Last Update Posted: March 8, 2023
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lyvgen Biopharma Holdings Limited:
Additional relevant MeSH terms:
Layout table for MeSH terms